| Literature DB >> 32739925 |
Jonathan H M van der Meer1, Karin A T G M Wasmann2, Jarmila D W van der Bilt2,3, Marte A J Becker1, Marja A Boermeester2, Willem A Bemelman2, Manon E Wildenberg1, Christianne J Buskens2.
Abstract
INTRODUCTION: Clinical trials are currently investigating whether an extended mesenteric resection for ileocecal resections could reduce postoperative recurrence in Crohn's disease. Resection of the mesorectum, which contains proinflammatory macrophages, during proct(ocol)ectomy, is associated with reduced recurrent inflammation and improved wound healing. We aimed to characterize the macrophages in the ileocecal mesentery, which were compared with those in the mesorectum, to provide a biological rationale for the ongoing trials.Entities:
Mesh:
Year: 2020 PMID: 32739925 PMCID: PMC7641506 DOI: 10.14309/ctg.0000000000000198
Source DB: PubMed Journal: Clin Transl Gastroenterol ISSN: 2155-384X Impact factor: 4.396
Figure 1.Mesenteric macrophages show a proinflammatory to regulatory gradient at the rectum, but this is inverted in the ileocecal region. (a) Schematic overview of mesorectal tissue sampling. (b) Mesorectal CD206+/CD206− ratios in control patients (n = 4: 3 suffering from ulcerative colitisand 1 from refractory constipation). (c) Mesorectal CD206+/CD206− ratios in patients with Crohn's disease (n = 13). *P < 0.05 compared with proximal, #P < 0.05 compared with distal ulcerative colitis (UC)/noninflammatory bowel disease (IBD) as calculated by t test. (d) Schematic overview of mesenteric tissue sampling in the ileocecal region. (e) CD206+/CD206− ratios in the ileocecal region of patients with UC or without IBD (n = 7: 3 suffering from ulcerative colitis, 2 from refractory constipation, and 2 from a cecal adenoma/carcinoma). (f) CD206+/CD206− ratios in the ileocecal region of patients with Crohn's disease with terminal ileitis (n = 38). **P < 0.01, compared with terminal ileum; #P < 0.05, compared with central UC/non-IBD as calculated by t-test.
Patient characteristics
Figure 2.B1 and L3 disease are associated with low CD206+/CD206− ratios throughout the ileocecal mesentery. (a) CD206 ratios in patients with L1 (n = 28) and L3 (n = 10) disease, compared with ulcerative colitis (UC)/non-inflammatory bowel disease (IBD) controls (n = 7). (b) CD206+/CD206− ratios in patients with recurrence, defined as a Rutgeerts score ≥ i2b (n = 9), vs patients without recurrence, defined as a Rutgeerts score ≤ i2a (n = 26), compared with UC/non-IBD controls (n = 7). (c) CD206+/CD206− ratios in patients with B1 (n = 4), B2 (n = 20), and B3 (n = 14) disease, compared with UC/non-IBD controls (n = 7). *P < 0.05; **P < 0.01, compared with UC/non-IBD controls as calculated by t test.